CAS: 31270-80-1; 4-Chlorofuro[3,2-C]Pyridine

相似化合物

220939-72-0 1187830-64-3 59760-41-7

上下游产品

CAS号26956-43-4 4,5-二氢-4-氧代呋喃[3,2]吡啶 | CAS号59898-36-1 3-(furan-2-yl)p... | CAS号20689-54-7 3-(furan-2-yl)p... | CAS号539-47-9 2-呋喃丙烯酸 | CAS号98-01-1 糠醛 | CAS号29080-01-1 2-(2'--Furyl)-1... | CAS号33007-15-7 7-hydroxy-6,7-d... | CAS号36953-42-1 3-溴-4-氯吡啶 | CAS号220939-72-0 3-溴-4-氯呋喃并[3,2-c]吡啶 | CAS号271-92-1 呋喃[3,2-C]吡啶 | CAS号81078-84-4 4-哌嗪-1-基-呋喃并吡啶 | CAS号33007-09-9 呋喃[3,2-c]吡啶-4-胺 | CAS号42398-75-4 7-methoxyisoqui... | CAS号86518-07-2 4-氯呋喃并[3,2-c]吡啶-2-甲醛 | CAS号86518-08-3 4-氯呋喃并[3,2-c]吡啶-2-羧酸 | CAS号799293-73-5 3-溴呋喃并[3,2-c]吡啶-4-胺

呋喃-2-丙烯酸叠氮化物置于三正丁胺,三氯氧磷体系中,化学反应 13.0H,反应生成 4-氯呋喃基吡啶
参考文献:新型基于呋喃并[3,2-C]吡啶的铱配合物,用于高性能有机发光二极管,具有超过30%的外部量子效率
标题:新型基于呋喃并[3,2-C]吡啶的铱配合物,用于高性能有机发光二极管,具有超过30%的外部量子效率
摘要:一种新的基于呋喃[3,2-C]吡啶的ir配合物,即(pfupy)2Ir(acac),已通过在c ^ N配体中用氧替代硫而得到开发.与含噻吩的(pthpy)2Ir(acac)相比,Lumo含量升高,而homo含量几乎保持不变.结果,发射最大值从(pthpy)2Ir(acac)的556 Nm蓝移到(pfupy)2Ir(acac)的538 Nm,同时提高了0.80的光致发光量子产率.基于(pfupy)2Ir(acac)的相应器件无需任何外耦合技术即可实现创纪录的30.5%(110.5 Cd / A)的外部量子效率(eqe).即使在1000和5000 Cd / M2的亮度下,Eqe仍分别保持在26.6%(96.4 Cd / A)和25.6%(92.7 Cd / A),表明效率下降缓慢.
DOI:10.1039/c7Tc03937A

专利信息

专利号:WO-2023091726-A1
优先权日:2021-11-18
标题:Inhibitors of cyclin‑dependent kinase 12 (cdk12)
发明人：BENOIT GUILLAUME; CARULLI JOHN; CHEN FEI; CHUAQUI CLAUDIO; CIBLAT STEPHANE; COOPER ELLIOT; DAGENAIS ROBIN; HU SHANHU; KABRO ANZHELIKA; LAPLACA DEREK; MARINEAU JASON; MOEBIUS DAVID; MOON DIANE; SOLODININ ANDREI; WHITMORE KENNETH
权利人:SYROS PHARMACEUTICALS INC
摘要:The present invention provides chemical compounds that inhibit one or more families of kinases (e.g., serine/threonine kinases, including one or more of the families of CDK proteins, and in particular, CDK12). More specifically, the present invention provides CDK12 inhibitors, of formula (I), pharmaceutically acceptable salts and isotopically labeled derivatives thereof, pharmaceutical compositions containing the compounds/inhibitors, and methods of their synthesis and use in treating proliferative diseases (e.g., a bladder cancer, a breast cancer, Ewing's sarcoma, a gastric cancer, a gastrointestinal cancer, a hematologic cancer, a lung cancer (e.g., small cell lung cancer (SCLC)), an ovarian cancer (e.g., a high grade serous ovarian cancer), a pancreatic cancer (e.g., pancreatic ductal adenocarcinoma (PDAC)), a brain cancer (e.g., glioblastoma), or a prostate cancer), alone or in combination with a second therapeutic agent. The proliferative disease can be a cancer, benign neoplasm, or pathologic angiogenesis, and any of the therapeutic methods or uses described herein can include a step of diagnosing the patient's disease. In other embodiments of the invention, the compositions described herein (e.g., the compounds, pharmaceutical compositions, and kits containing them) are used for the treatment of myotonic dystrophy (type 1 or type 2).

专利号:US-6936600-B2
优先权日:1999-04-01
标题:Sorbitol dehrydrogenase inhibitors
发明人：CHU-MOYER MARGARET Y; MYLARI BANAVARA L; ZEMBROWSKI WILLIAM J
权利人:PFIZER
摘要:This invention is directed to sorbitol dehydrogenase inhibitory compounds of the formula I, n n nwherein R 1 , R 2 and R 3 are as defined in the specification. This invention is also directed to pharmaceutical compositions containing those compounds and methods of treating or preventing diabetic complications, particularly diabetic neuropathy, diabetic nephropathy, diabetic microangiopathy, diabetic macroangiopathy and diabetic cardiomyopathy by administering such compounds to a mammal suffering from diabetes and therefore at risk for developing such complications. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of this invention with an aldose reductase inhibitor and to methods of treating or preventing diabetic complications therewith. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of this invention with an NHE-1 inhibitor and to methods of treating cardiomyopathy and other heart-related problems therewith. This invention is also directed to certain intermediates used in the synthesis of the compounds of formula I and to processes for preparing those intermediates.